Cohance plans USD 18 million ADC investment push
In short
Cohance Lifesciences said it plans to invest USD 18 million more to support its ADC strategy. That includes USD 13 million in NJ Bio and USD 5 million for a controlling investment in Aruka Bio, and it says the money will come from internal accruals.
This matters because the company is trying to build up its antibody-drug conjugate business. The report does not say when the deals will close or what results it expects.
What the reporting says
Cohance Lifesciences announced two proposed investments totaling USD 18 million to strengthen its ADC strategy. The company said it will invest USD 13 million more in NJ Bio and USD 5 million for a controlling stake in Aruka Bio, with both transactions funded through internal accruals. The immediate consequence is strategic expansion, but closing timing and integration details are not stated.
Why it matters
Cohance Lifesciences announced two proposed transactions to deepen its antibody-drug conjugate strategy: an additional USD 13 million investment in NJ Bio and a USD 5 million controlling investment in Aruka Bio. Both deals are to be funded through internal accruals. The move signals strategic buildup in a specialized drug area, but the reporting does not state completion dates or operational benefits.